Drug intelligence / Profile preview

LBI-1103

Development stage: Preclinical
Lead developer: Austin Biosciences
Modality: Small Molecules

Overview

LBI-1103 is an advanced, first-in-class, second-generation taxane-based chemotherapy being developed by Austin Biosciences. As a small molecule chemotherapy, it is designed with an immediate-release formulation and incorporates drug resistance and targeting sensitizers to enhance therapeutic efficacy. The drug is currently in the pre-clinical stage, with animal testing for maximum tolerated dose (MTD) and dosing schedule optimization underway. LBI-1103 is being investigated for the treatment of multiple solid tumors, including prostate, breast, lung, head and neck, ovarian, and stomach cancers.

Targets

TUBB (Tubulin (alpha and beta subunits))

Beyond the preview

Go deeper on LBI-1103.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LBI-1103.

Explore the full profile